Kiromic Biopharma Current Ratio vs. Cash Flow From Operations

KRBPDelisted Stock  USD 2.68  0.07  2.55%   
Based on the key profitability measurements obtained from Kiromic Biopharma's financial statements, Kiromic Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Kiromic Biopharma's ability to earn profits and add value for shareholders.
For Kiromic Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiromic Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiromic Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiromic Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiromic Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Please note, there is a significant difference between Kiromic Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiromic Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiromic Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kiromic Biopharma Cash Flow From Operations vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kiromic Biopharma's current stock value. Our valuation model uses many indicators to compare Kiromic Biopharma value to that of its competitors to determine the firm's financial worth.
Kiromic Biopharma is rated below average in current ratio category among its peers. It is rated below average in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Kiromic Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Kiromic Cash Flow From Operations vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Kiromic Biopharma

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
1.35 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Kiromic Biopharma

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(23.75 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Kiromic Cash Flow From Operations Comparison

Kiromic Biopharma is currently under evaluation in cash flow from operations category among its peers.

Kiromic Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kiromic Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiromic Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Kiromic Biopharma's change in net profit over the period of time. It can combine multiple indicators of Kiromic Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.

Kiromic Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kiromic Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiromic Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiromic Biopharma's important profitability drivers and their relationship over time.

Use Kiromic Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.

Kiromic Biopharma Pair Trading

Kiromic Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kiromic Biopharma position

In addition to having Kiromic Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals Thematic Idea Now

Precious Metals
Precious Metals Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Kiromic Stock

If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device